Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study

Background  Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of major bleeding by decreasing platelet function or decreasing vitamin K antagonist (VKA) metabolism via cytochrome P450 (CYP) inhibition. Aims  To determine whether SSRIs are associated with major bleeding during VKA...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakker, Sanne, Burggraaf, Johanna Louise I., Kruip, Marieke J. H. A., van der Meer, Felix J. M., Lijfering, Willem M., van Rein, Nienke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904966/
https://www.ncbi.nlm.nih.gov/pubmed/36208621
http://dx.doi.org/10.1055/a-1957-6305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904966/
https://www.ncbi.nlm.nih.gov/pubmed/36208621
http://dx.doi.org/10.1055/a-1957-6305

Ejemplares similares